Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, now holds B shares in Novozymes A/S to a total of 24,556,257 shares of a nominal value of DKK 49,112,514, equivalent to 7.56% of Novozymes A/S’ share capital and 3.04% of the voting rights. The announcement is a result of Baillie Gifford Overseas Limited, a wholly owned subsidiary of Baillie Gifford & Co, increasing its holding of B shares in Novozymes A/S to a total of 16,349,463 B shares of a nominal value of DKK 32,698,926, equivalent to 5.03% of Novozymes share capital.
Major Shareholder Announcement
In accordance with section 29 of the Danish Securities Trading Act, Novozymes hereby announces that it has been informed that Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, has decreased its holding of B shares in Novozymes to 7.56%, previously reported at 7.64% (a decrease of 0.08%).
| Quelle: Novonesis (Novozymes A/S)
Anhänge
